Next-Generation Cancer Treatments
Our proprietary Antibody-Prodrug Conjugate, or APDC, platform is designed to keep therapies inactive in the body until they reach the tumor microenvironment, helping reduce systemic toxicity while preserving therapeutic potency.
Precision Delivery
Advanced antibody targeting supports precise delivery to cancer cells while adding an extra layer of biological selectivity through tumor-triggered activation.
Selective Activation
Our prodrug-based approach is engineered to activate only within tumor microenvironments, helping focus therapeutic activity where it matters most.
Reduced Toxicity
By replacing highly toxic payloads with low- or non-toxic prodrugs, APDC is designed to reduce systemic exposure and off-target side effects.
Platform Innovation
Our technology opens the possibility of using potent therapeutic mechanisms that may otherwise be too toxic in conventional ADC formats.